https://www.stormtherapeutics.com/ https://www.stormtherapeutics.com/about/ https://www.stormtherapeutics.com/platform/ https://www.stormtherapeutics.com/news/ https://www.stormtherapeutics.com/careers/ https://www.stormtherapeutics.com/contact/ https://www.stormtherapeutics.com/about/board-members/ https://www.stormtherapeutics.com/about/leadership-team/ https://www.stormtherapeutics.com/about/investors/ https://www.stormtherapeutics.com/about/investors/m-ventures/ https://www.stormtherapeutics.com/about/investors/cambridge-innovation-capital-i-limited/ https://www.stormtherapeutics.com/about/investors/pfizer-venture-investments/ https://www.stormtherapeutics.com/privacy-policy/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-ceo-and-chairman/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-raises-12-million-series-a-funding-to-develop-novel-cancer-therapeutics/ https://www.stormtherapeutics.com/news/press-releases/the-power-of-rna-epigenetics-highlighted-in-two-articles-in-nature-magazine/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-and-evotec-collaborate-on-its-rna-epigenetic-platform/ https://www.stormtherapeutics.com/news/storm-in-the-news/biocentury-emerging-company-profile-taking-rna-epigenetics-by-storm/ https://www.stormtherapeutics.com/news/storm-in-the-news/pharma-tv-storm-therapeutics-a-pioneer-in-the-field-of-rna-epigenetics/ https://www.stormtherapeutics.com/news/press-releases/ https://www.stormtherapeutics.com/news/storm-in-the-news/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-wins-biotech-start-up-at-cambridge-independent-entrepreneurial-science-and-technology-awards/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-strengthens-board-with-appointment-of-professor-paul-workman-president-and-ceo-of-the-institute-of-cancer/ https://www.stormtherapeutics.com/news/press-releases/attacking-diseases-by-inhibiting-rna-modification/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-publication-in-nature-on-rna-epigenetics-by-founder-professor-tony-kouzarides/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-appointments-to-scientific-advisory-board/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-extends-series-a-round-to-include-new-investor-taiho-ventures/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-distinguished-professor-and-nobel-prize-winner-professor-thomas-cech-as-scientific-advisor/ https://www.stormtherapeutics.com/news/storm-in-the-news/biotech-and-money-executive-expert-insights-storm-therapeutics-leads-the-way-in-rna-epigenetics/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-wins-life-science-innovation-award/ https://www.stormtherapeutics.com/news/storm-in-the-news/storm-ceo-outlines-business-model-and-pipeline-goals/ https://www.stormtherapeutics.com/about/investors/ip-group/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-at-bio-quity-europe-2018/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-and-the-university-of-cambridge-receive-innovate-uk-funding-to-help-the-fight-against-cancer/ https://www.stormtherapeutics.com/pipeline/ https://www.stormtherapeutics.com/about/team/ https://www.stormtherapeutics.com/about/team/tim-edwards/ https://www.stormtherapeutics.com/about/team/hakan-goker-phd/ https://www.stormtherapeutics.com/about/team/sakae-asanuma/ https://www.stormtherapeutics.com/about/team/professor-tony-kouzarides-phd-fmedsci-frs/ https://www.stormtherapeutics.com/about/team/professor-eric-miska-phd/ https://www.stormtherapeutics.com/about/team/professor-paul-workman-frs-fmedsci/ https://www.stormtherapeutics.com/about/team/oliver-rausch-phd/ https://www.stormtherapeutics.com/about/team/professor-mark-dawson/ https://www.stormtherapeutics.com/about/team/paul-leeson-phd/ https://www.stormtherapeutics.com/about/team/professor-thomas-cech-phd/ https://www.stormtherapeutics.com/about/investors/taiho-ventures-llc/ https://www.stormtherapeutics.com/platform/publications/ https://www.stormtherapeutics.com/about/team/professor-thomas-carell-phd/ https://www.stormtherapeutics.com/news/storm-in-the-news/biocentury-storms-rna-modification-software/ https://www.stormtherapeutics.com/news/storm-in-the-news/chemical-engineering-news-epitranscriptomics-the-new-rna-code-and-the-race-to-drug-it/ https://www.stormtherapeutics.com/news/storm-in-the-news/nature-rna-epigenetics-spurs-investor-interest-but-uncertainties-linger/ https://www.stormtherapeutics.com/news/storm-in-the-news/biocentury-playing-in-rna/ https://www.stormtherapeutics.com/news/storm-in-the-news/apm-health-europe-rna-is-untapped-druggable-space-says-ceo-of-uks-storm-therapeutics/ https://www.stormtherapeutics.com/news/storm-in-the-news/global-university-venturing-war-on-cancer-is-the-end-in-sight/ https://www.stormtherapeutics.com/news/storm-in-the-news/genetic-engineerig-biotechnology-news-epigenetic-therapies-return-cells-to-the-straight-and-narrow/ https://www.stormtherapeutics.com/news/storm-in-the-news/biocentury-the-academic-founders-conundrum/ https://www.stormtherapeutics.com/news/storm-in-the-news/molecular-cell-mettl1-promotes-let-7-microrna-processing-via-m7g-methylation/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-extends-series-a-to-gbp-30m-usd-38.43m-with-new-investor-seroba-life-sciences/ https://www.stormtherapeutics.com/about/team/christopher-odonnell-phd/ https://www.stormtherapeutics.com/news/storm-in-the-news/wuxi-apptec-storm-therapeutics-pioneering-new-rna-pathways-to-novel-therapies/ https://www.stormtherapeutics.com/about/investors/seroba-life-sciences/ https://www.stormtherapeutics.com/news/storm-in-the-news/nature-biotechnology-nature-biotechnologys-academic-spinouts-of-2018/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-dr-john-haurum-to-the-board-of-directors/ https://www.stormtherapeutics.com/news/storm-in-the-news/labiotech-meet-the-first-company-in-the-brand-new-field-of-epitranscriptomics/ https://www.stormtherapeutics.com/news/storm-in-the-news/biocentury-innovations-a-mark-up-for-rna-epigenetics/ https://www.stormtherapeutics.com/news/storm-in-the-news/wuxi-apptec-rna-focused-drug-development-emerging-as-a-dominant-treatment-modality/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-host-first-rna-epigenetics-conference-in-cambridge-uk/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-presents-breakthrough-data-showing-in-vivo-efficacy-and-therapeutic-proof-of-concept-for-targeting-rna/ https://www.stormtherapeutics.com/platform/overview/ https://www.stormtherapeutics.com/platform/rna-modifying-enzymes/ https://www.stormtherapeutics.com/news/storm-in-the-news/rna-epigenetics-is-coming-of-age/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-collaborator-awarded-ash-bsh-abstract-achievement-award-at-the-61st-ash-annual-meeting-exposition/ https://www.stormtherapeutics.com/news/storm-in-the-news/bia-report-global-and-growing-uk-biotech-financing-in-2019/ https://www.stormtherapeutics.com/news/press-releases/analysis-of-rna-sequences-and-modifications-by-mass-spectrometry-published-in-nature-communications/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-publication-in-nature-reviews-cancer-on-the-role-of-rna-modifications-in-cancer-by-founder/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-dr-angus-lauder-as-director-of-business-development/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-dr-josefin-beate-holz-as-chief-medical-officer/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-at-two-scientific-conferences-in-july-2020/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-selects-first-in-class-clinical-candidate-targeting-mettl3/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-virtual-conference-calendar/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-publication-of-rna-modifying-enzymes-and-their-inhibitors-in-2020-medicinal-chemistry-reviews/ https://www.stormtherapeutics.com/news/storm-in-the-news/storm-therapeutics-nominated-as-one-of-the-finalists-for-the-bionewsround-award-2020/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-expands-scientific-advisory-board-with-the-appointment-of-professor-tsutomu-suzuki/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-publishes-data-in-nature-showing-its-first-in-class-inhibitor-of-mettl3-is-effective-as-a-new-therapeutic/ https://www.stormtherapeutics.com/news/storm-in-the-news/scrip-intelligence-storms-mettl3-inhibitor-effective-against-aml/ https://www.stormtherapeutics.com/news/storm-in-the-news/drughunter-small-molecules-of-the-month-apr-2021/ https://www.stormtherapeutics.com/news/storm-in-the-news/royal-society-of-chemistry-designing-cancer-drugs/ https://www.stormtherapeutics.com/news/press-releases/exelixis-and-storm-therapeutics-enter-into-exclusive-collaboration-and-license-agreement-to-discover-and-develop-inhibitors-of/ https://www.stormtherapeutics.com/about/team/jerry-mcmahon-phd/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-awarded-innovate-uk-grant-to-discover-and-develop-a-novel-coronavirus-therapy-targeting-an-rna-modifying/ https://www.stormtherapeutics.com/platform/publications/storm-publications/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/the-viral-rna-capping-machinery-as-a-target-for-antiviral-drugs/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/loss-of-adar1-in-tumours-overcomes-resistance-to-immune-checkpoint-blockade-jan-2019-nature/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/m6-a-rna-methyltransferases-mettl3-14-regulate-immune-responses-to-anti-pd-1-therapy-oct-2020-embo-j/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/role-of-rna-modifications-in-cancer-jun-2020-nat-rev-cancer/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/the-expanding-world-of-trna-modifications-and-their-disease-relevance-jun-2021-nat-rev-mol-cell-biol/ https://www.stormtherapeutics.com/platform/publications/other-relevant-publications/a-call-for-direct-sequencing-of-full-length-rnas-to-identify-all-modifications-aug-2021-nat-genet/ https://www.stormtherapeutics.com/platform/publications/storm-publications/rna-uridyl-transferases-tut4-7-differentially-regulate-mirna-variants-depending-on-the-cancer-cell-type-mar-2022-rna/ https://www.stormtherapeutics.com/platform/publications/storm-publications/small-molecule-inhibition-of-mettl3-as-a-strategy-against-myeloid-leukaemia-may-2021-nature/ https://www.stormtherapeutics.com/platform/publications/storm-publications/genome-wide-investigation-of-gene-cancer-associations-for-the-prediction-of-novel-therapeutic-targets-in-oncology-jul-2020-sci/ https://www.stormtherapeutics.com/platform/publications/storm-publications/a-computational-platform-for-high-throughput-analysis-of-rna-sequences-and-modifications-by-mass-spectrometry-feb-2020-nat/ https://www.stormtherapeutics.com/platform/publications/storm-publications/rna-modifying-enzymes-and-their-function-in-a-chromatin-context-oct-2019-nat-struct-mol-biol/ https://www.stormtherapeutics.com/platform/publications/storm-publications/promoter-bound-mettl3-maintains-myeloid-leukaemia-by-m6a-dependent-translation-control-dec-2017-nature/ https://www.stormtherapeutics.com/about/scientific-founders-advisors/ https://www.stormtherapeutics.com/news/events/proteomics-in-cell-biology-and-disease-mechanism/ https://www.stormtherapeutics.com/news/events/eortc-nci-aacr-symposium/ https://www.stormtherapeutics.com/news/events/sitc-society-for-immunotherapy-of-cancer/ https://www.stormtherapeutics.com/news/events/lsx-investival-showcase/ https://www.stormtherapeutics.com/news/events/jefferies-london-healthcare-conference/ https://www.stormtherapeutics.com/news/events/esmo/ https://www.stormtherapeutics.com/about/investors/fast-track-initiative/ https://www.stormtherapeutics.com/about/investors/utokyo-innovation-platform-co-ltd/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-dr-jerry-mcmahon-as-chief-executive-officer/ https://www.stormtherapeutics.com/news/press-releases/fierce-biotech-names-storm-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2022/ https://www.stormtherapeutics.com/news/events/fierce-biotech-summit-fierce-15-winners-award-presentation/ https://www.stormtherapeutics.com/news/events/american-association-for-cancer-research-aacr-special-conference-acute-myeloid-leukemia-and-myelodysplastic-syndrome/ https://www.stormtherapeutics.com/news/events/american-academy-of-allergy-asthma-immunology-aaaai-annual-meeting-2023/ https://www.stormtherapeutics.com/news/events/american-association-for-cancer-research-aacr-annual-meeting-2023/ https://www.stormtherapeutics.com/news/events/american-society-of-clinical-oncology-asco-annual-meeting-2023/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-new-data-on-its-lead-program-stc-15-at-the-34th-eortc-nci-aacr-symposium-and-the-37th-sitc-meeting/ https://www.stormtherapeutics.com/platform/publications/storm-publications/stc-15-an-oral-small-molecule-inhibitor-of-the-rna-methyltransferase-mettl3-inhibits-tumour-growth-through-activation-of-anti/ https://www.stormtherapeutics.com/platform/publications/storm-publications/stc-15-an-oral-small-molecule-inhibitor-of-the-rna-methyltransferase-mettl3-inhibits-tumour-growth-through-activation-of-anti-1/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-doses-first-patient-with-oral-mettl3-targeting-drug-candidate-in-a-solid-tumor-phase-1-study/ https://www.stormtherapeutics.com/about/team/beth-thomas-phd/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-closing-of-usd-30m-series-b-financing/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-expands-r-d-leadership-team/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-presents-stc-15-preclinical-data-supporting-treatment-of-patients-with-aml-at-the-aacr-acute-myeloid/ https://www.stormtherapeutics.com/platform/publications/storm-publications/stc-15-a-novel-mettl3-inhibitor-and-its-combination-with-venetoclax-confer-anti-tumour-activity-in-aml-models-jan-2023/ https://www.stormtherapeutics.com/news/events/acute-leukemias-xviii-biology-and-treatment-strategies/ https://www.stormtherapeutics.com/news/events/bio-europe-spring/ https://www.stormtherapeutics.com/news/events/immuno-2023/ https://www.stormtherapeutics.com/news/events/frontiers-in-medicinal-chemistry/ https://www.stormtherapeutics.com/news/events/bio-quity-europe/ https://www.stormtherapeutics.com/news/events/medicinal-chemistry-gordon-research-conference/ https://www.stormtherapeutics.com/news/events/acs-fall-2023/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-publishes-data-in-cancer-discovery-showing-induction-of-anti-tumour-immunity-by-mettl3-inhibition/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-the-discovery-of-lead-clinical-candidate-stc-15-at-the-american-chemical-society-fall-2023/ https://www.stormtherapeutics.com/news/events/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ https://www.stormtherapeutics.com/platform/publications/storm-publications/stc-15-a-small-molecule-inhibitor-of-the-rna-methyltransferase-mettl3-activates-anti-tumor-immunity-and-reshapes-the-tumor/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-presented-novel-pre-clinical-data-on-stc-15-at-the-aacr-nci-eortc-international-conference-on-molecular/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-marguerite-hutchinson-j.d-as-chief-business-officer/ https://www.stormtherapeutics.com/about/team/marguerite-hutchinson-j.d/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-first-in-class-trna-methyltransferase-inhibitor-of-mettl1-to-be-presented-at-the-65th-annual-ash-conference/ https://www.stormtherapeutics.com/clinical-trials/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-findings-on-its-first-in-class-mettl1-trna-methyltransferase-inhibitors-at-esmo-targeted/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-data-on-its-first-in-class-mettl1-trna-methyltransferase-inhibitors-at-aacr-annual-meeting-2024/ https://www.stormtherapeutics.com/news/storm-in-the-news/drug-discovery-world-conversations-from-esmo-targeted-anticancer-therapies-congress-2024/ https://www.stormtherapeutics.com/news/storm-in-the-news/the-medicine-maker-the-power-list-2024/ https://www.stormtherapeutics.com/platform/publications/storm-publications/phase-1-dose-escalation-and-cohort-expansion-study-evaluating-safety-pk-pd-and-clinical-activity-of-stc-15-a-mettl-3-inhibitor-1/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024/ https://www.stormtherapeutics.com/platform/publications/storm-publications/inhibiting-coronavirus-5-rna-capping-with-potent-selective-fic-small-molecules-may-2024-4th-sci-rsc-symposium-on-anti-infectives/ https://www.stormtherapeutics.com/platform/publications/storm-publications/phase-1-dose-escalation-and-cohort-expansion-study-evaluating-safety-pk-pd-and-clinical-activity-of-stc-15-a-mettl-3-inhibitor/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-presented-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024/ https://www.stormtherapeutics.com/news/press-releases/tony-kouzarides-founder-of-storm-therapeutics-awarded-british-knighthood-for-services-to-healthcare-innovation-and-delivery/ https://www.stormtherapeutics.com/news/storm-in-the-news/optimum-tv-modifying-rna-with-small-molecule-drugs-a-new-approach-to-immunotherapy/ https://www.stormtherapeutics.com/news/storm-in-the-news/drug-discovery-world-aacr-a-focal-point-of-the-cancer-research-community/ https://www.stormtherapeutics.com/news/storm-in-the-news/medical-technology-asco-2024-unveils-practice-changing-research-in-oncology/ https://www.stormtherapeutics.com/news/storm-in-the-news/drug-hunter-targeting-post-transcriptional-rna-modification-with-a-first-to-clinic-mettl3-inhibitor-stc15/ https://www.stormtherapeutics.com/news/events/efmc-ismc-2024-international-symposium-on-medicinal-chemistry/ https://www.stormtherapeutics.com/news/events/european-conference-on-computational-biology-eccb-2024/ https://www.stormtherapeutics.com/news/events/elrig-drug-discovery-2024/ https://www.stormtherapeutics.com/news/storm-in-the-news/drug-discovery-world-beyond-immunotherapy-could-rna-modifying-enzymes-boost-response-rates/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-to-present-phase-1-data-on-its-first-in-class-lead-product-stc-15-at-eortc-nci-aacr-symposium/ https://www.stormtherapeutics.com/platform/publications/storm-publications/working-towards-pandemic-preparedness-inhibiting-viral-5-rna-cap-methylation-with-potent-selective-broad-spectrum-anti-viral/ https://www.stormtherapeutics.com/platform/publications/storm-publications/first-results-of-a-phase-1-study-evaluating-safety-pk-pd-and-clinical-activity-of-stc-15-a-mettl3-inhibitor-in-patients/ https://www.stormtherapeutics.com/platform/publications/storm-publications/phase-1-dose-escalation-and-cohort-expansion-study-evaluating-safety-pk-pd-and-clinical-activity-of-stc-15-a-mettl3-inhibitor/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-presents-new-clinical-data-on-its-first-in-class-mettl3-inhibitor-stc-15-at-sitc-2024/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-first-patient-dosed-in-clinical-collaboration-to-evaluate-stc-15-in-combination-with-loqtorzi/ https://www.stormtherapeutics.com/about/team/atif-abbas-md/ https://www.stormtherapeutics.com/about/team/eric-martin-phd/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-appoints-veteran-cancer-drug-developer-dr-eric-martin-as-chief-development-officer/ https://www.stormtherapeutics.com/platform/publications/storm-publications/an-arrayed-crispr-screen-identifies-rna-based-regulators-of-the-alternative-lengthening-of-telomeres-pathway/ https://www.stormtherapeutics.com/platform/publications/storm-publications/discovery-of-an-allosteric-potent-and-selective-dhx9-helicase-inhibitor-with-best-in-class-potential-for-the-treatment-of/ https://www.stormtherapeutics.com/platform/publications/storm-publications/a-phase-1b-2-dose-escalation-and-expansion-study-of-stc-15-a-mettl3-inhibitor-in-combination-with-toripalimab-an-anti-pd-1/ https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-and-alidabio-announce-strategic-collaboration-to-accelerate-development-of-cancer-therapies-targeting-rna/